Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 954

1.

Evaluation of Cardiovascular Disease Risk in HIV-1-Infected Patients Treated with Darunavir.

Opsomer M, Dimitrova D, Verspeelt J, Purrington A, Mehbob A, Chavers S, Pai H, Vanveggel S, Luo D, Brown K, Moecklinghoff C, Nettles RE, Boven K.

Drugs R D. 2018 Jul 10. doi: 10.1007/s40268-018-0238-8. [Epub ahead of print]

PMID:
29992490
2.

Correction to: Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication.

Guitart J, Vargas MI, De Sanctis V, Folch J, Salazar R, Fuentes J, Coma J, Ferreras J, Moya J, Tomás A, Estivill P, Rodelas F, Jiménez AJ, Sanz A.

Drugs R D. 2018 Jul 9. doi: 10.1007/s40268-018-0239-7. [Epub ahead of print]

PMID:
29987670
3.

Octreotide Use in Neonates: A Case Series.

Zaki SA, Krishnamurthy MB, Malhotra A.

Drugs R D. 2018 Jun 15. doi: 10.1007/s40268-018-0237-9. [Epub ahead of print]

PMID:
29948779
4.

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers.

Cullberg M, Arfvidsson C, Larsson B, Malmgren A, Mitchell P, Wählby Hamrén U, Wray H.

Drugs R D. 2018 Jun;18(2):149-159. doi: 10.1007/s40268-018-0236-x.

5.

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.

Buti S, Donini M, Bersanelli M, Gattara A, Leonardi F, Passalacqua R.

Drugs R D. 2018 Jun;18(2):163. doi: 10.1007/s40268-018-0234-z.

6.

Co-crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre, Phase II Trial.

López-Cedrún J, Videla S, Burgueño M, Juárez I, Aboul-Hosn S, Martín-Granizo R, Grau J, Puche M, Gil-Diez JL, Hueto JA, Vaqué A, Sust M, Plata-Salamán C, Monner A; Co-Crystal of Tramadol-Celecoxib Team.

Drugs R D. 2018 Jun;18(2):137-148. doi: 10.1007/s40268-018-0235-y.

7.

Correction to: The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.

Auffret M, Drapier S, Vérin M.

Drugs R D. 2018 Jun;18(2):161. doi: 10.1007/s40268-018-0233-0.

8.
9.

Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication.

Guitart J, Vargas MI, De Sanctis V, Folch J, Salazar R, Fuentes J, Coma J, Ferreras J, Moya J, Tomás A, Estivill P, Rodelas F, Jiménez AJ, Sanz A.

Drugs R D. 2018 Jun;18(2):119-128. doi: 10.1007/s40268-018-0231-2. Erratum in: Drugs R D. 2018 Jul 9;:.

10.

The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.

Auffret M, Drapier S, Vérin M.

Drugs R D. 2018 Jun;18(2):91-107. doi: 10.1007/s40268-018-0230-3. Review. Erratum in: Drugs R D. 2018 May 8;:.

11.

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment.

Marcinak J, Vakilynejad M, Kogame A, Tagawa Y.

Drugs R D. 2018 Jun;18(2):109-118. doi: 10.1007/s40268-018-0229-9.

12.

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes.

Liebl A, Mohan V, Yang W, Strojek K, Linjawi S.

Drugs R D. 2018 Mar;18(1):27-39. doi: 10.1007/s40268-018-0228-x. Review.

14.
15.

In Vitro Safety Pharmacology Profiling of Topical α-Adrenergic Agonist Treatments for Erythema of Rosacea.

Piwnica D, Pathak A, Schäfer G, Docherty JR.

Drugs R D. 2018 Mar;18(1):87-90. doi: 10.1007/s40268-018-0227-y.

16.

Second-Hand Exposure of Staff Administering Vaporised Cannabinoid Products to Patients in a Hospital Setting.

Solowij N, Galettis P, Broyd SJ, de Krey P, Martin JH.

Drugs R D. 2018 Mar;18(1):41-44. doi: 10.1007/s40268-017-0225-5.

17.

The Risk of Thrombocytopenia During Valproic Acid Therapy: A Critical Summary of Available Clinical Data.

Buoli M, Serati M, Botturi A, Altamura AC.

Drugs R D. 2018 Mar;18(1):1-5. doi: 10.1007/s40268-017-0224-6.

18.

Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.

Garimella T, Tao X, Sims K, Chang YT, Rana J, Myers E, Wind-Rotolo M, Bhatnagar R, Eley T, LaCreta F, AbuTarif M.

Drugs R D. 2018 Mar;18(1):55-65. doi: 10.1007/s40268-017-0222-8.

19.

Sealing Effects on the Storage Stability of the Cyanide Antidotal Candidate, Dimethyl Trisulfide.

Kiss L, Duke A, Kovacs K, Barcza T, Kiss M, Petrikovics I, Thompson DE.

Drugs R D. 2018 Mar;18(1):45-49. doi: 10.1007/s40268-017-0220-x.

20.

Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.

Rodríguez-Portal JA.

Drugs R D. 2018 Mar;18(1):19-25. doi: 10.1007/s40268-017-0221-9.

Supplemental Content

Loading ...
Support Center